| MeSH term | MeSH ID | Detail |
|---|---|---|
| Dendritic Cell Sarcoma, Interdigitating | D054739 | 1 associated lipids |
| Polymyositis | D017285 | 1 associated lipids |
| Scorpion Stings | D065008 | 1 associated lipids |
| Rotavirus Infections | D012400 | 1 associated lipids |
| Netherton Syndrome | D056770 | 1 associated lipids |
| Pseudohypoaldosteronism | D011546 | 1 associated lipids |
| Arm Injuries | D001134 | 1 associated lipids |
| Intussusception | D007443 | 1 associated lipids |
| Thrombotic Microangiopathies | D057049 | 1 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Miyauchi T et al. | Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. | 1998 | Transplantation | pmid:9448139 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Boyer O et al. | Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. | 2005 | Transplantation | pmid:15912111 |
| Numakura K et al. | Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. | 2005 | Transplantation | pmid:16340785 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| de Sandes-Freitas TV et al. | Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. | 2015 | Transplantation | pmid:25929604 |
| Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
| van Rijen MM et al. | CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. | 2002 | Transplantation | pmid:12042657 |
| Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
| Bäckman L et al. | FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. | 1994 | Transplantation | pmid:7509516 |
| Higgins RM et al. | Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. | 2004 | Transplantation | pmid:14966430 |
| Abadja F et al. | Impact of mycophenolic acid and tacrolimus on Th17-related immune response. | 2011 | Transplantation | pmid:21818055 |
| Jain AB et al. | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. | 1998 | Transplantation | pmid:9846530 |
| Schena FP et al. | Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. | 2009 | Transplantation | pmid:19155978 |
| Fridell JA et al. | Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. | 2002 | Transplantation | pmid:12499888 |
| Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
| Arai K et al. | Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. | 1989 | Transplantation | pmid:2479130 |
| Mendez R et al. | A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. | 2005 | Transplantation | pmid:16082323 |
| Oku M et al. | Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. | 2012 | Transplantation | pmid:22158517 |